奥美拉唑

奥美拉唑用途

Omeprazole(Prilosec)是质子泵抑制剂,可作用于消化不良。

点击显示

奥美拉唑作用

①消化性溃疡出血、吻合口溃疡出血。
②应激状态时并发的急性胃黏膜损害，和非甾体类抗炎药引起的急性胃黏膜损伤；
③亦常用于预防重症疾病（如脑出血、严重创伤等）胃手术后预防再出血等；
④全身麻醉或大手术后以及衰弱昏迷患者防止胃酸反流合并吸入性肺炎。
5、胃酸过多患者导致反流性胃炎的酸抑制，以及胃酸过多造成的严重烧心患者。
6、消化性溃疡胃十二指肠糜烂者，在治疗中也常常会用到奥美拉唑。

点击显示

奥美拉唑名称

[ CAS 号 ]:
73590-58-6

[ 中文名 ]:
奥美拉唑

[ 英文名 ]:
omeprazole

[中文别名 ]:

[英文别名 ]:

Omepral
elgam
ANTRA
MEPRAL
Zoltum
[14C]-Omeprazole
PRILOSEC
zimor
Losec
Omeprazen

奥美拉唑生物活性

[ 描述 ]:

Omeprazole(Prilosec)是质子泵抑制剂,可作用于消化不良。

[ 相关类别 ]:

信号通路 >> 自噬 >> 自噬

信号通路 >> 跨膜转运 >> 质子泵

研究领域 >> 代谢疾病

[参考文献]

[1]. Walt, R.P., et al., Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J (Clin Res Ed), 1983. 287(6384): p. 12-4.

[2]. Howden, C.W., et al., Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol, 1984. 26(5): p. 641-3.

[相关活性小分子]

奥美拉唑物理化学性质

[ 密度 ]:
1.4±0.1 g/cm3

[ 沸点 ]:
600.0±60.0 °C at 760 mmHg

[ 熔点 ]:
156ºC

[ 分子式 ]:
C₁₇H₁₉N₃O₃S

[ 分子量 ]:
345.416

[ 闪点 ]:
316.7±32.9 °C

[ 精确质量 ]:
345.114716

[ PSA ]:
96.31000

[ LogP ]:
2.17

[ 外观性状 ]:
白色结晶固体

[ 蒸汽压 ]:
0.0±1.7 mmHg at 25°C

[ 折射率 ]:
1.669

[ 储存条件 ]:
2-8°C

[ 稳定性 ]:
Stable, but hygroscopic and photosensitive. Incompatible with strong oxidizing agents. Store in the dark.

[ 水溶解性 ]:
H2O: 0.5 mg/mL

奥美拉唑MSDS

详细MSDS(安全技术说明书)

奥美拉唑毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DD9087000

CHEMICAL NAME :: 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)met hyl)sulfinyl)-

CAS REGISTRY NUMBER :: 73590-58-6

LAST UPDATED :: 199806

DATA ITEMS CITED :: 15

MOLECULAR FORMULA :: C17-H19-N3-O3-S

MOLECULAR WEIGHT :: 345.45

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 800 ug/kg/2D-I

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 30 mg/kg/10W-I

TOXIC EFFECTS :: Blood - eosinophilia Kidney, Ureter, Bladder - interstitial nephritis Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 4 mg/kg/2W-I

TOXIC EFFECTS :: Musculoskeletal - joints Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2210 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - respiratory depression

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >100 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Gastrointestinal - hypermotility, diarrhea Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >100 mg/kg

TOXIC EFFECTS :: Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >50 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Gastrointestinal - hypermotility, diarrhea Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >4 gm/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >100 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >100 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - altered sleep time (including change in righting reflex) Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 82800 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 8320 mg/kg

SEX/DURATION :: female 17-20 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3520 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects

TYPE OF TEST :: DNA damage

MUTATION DATA

TEST SYSTEM :: Rodent - rat

DOSE/DURATION :: 100 mg/kg

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 262,73,1991

点击显示

奥美拉唑安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant;

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
DD9087000

奥美拉唑上下游产品

奥美拉唑上游产品

奥美拉唑下游产品

奥美拉唑制备

3，5-二甲基-2-羟甲基-4-甲氧基吡啶经氯化，生成2-氯甲基-3，5-二甲基-4-甲氧基吡啶。

4-甲氧基1，2-苯二胺和黄原酸钾反应，生成2-巯基-5-甲氧基苯并咪唑，再和上面得到的吡啶衍生物反应，生成2-[(3，5-二甲基-4-甲氧基-2-吡啶基)甲硫基]-5-甲氧基-1H-苯并咪唑，最后在氯仿中，5℃下，用间氯过苯甲酸氧化，得到奥美拉唑。粗品奥美拉唑可用乙腈重结晶。

点击显示

奥美拉唑文献

Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole.

Drug Metab. Dispos. 43 , 1408-16, (2015)

The common marmoset (Callithrix jacchus), a small New World monkey, has the potential for use in human drug development due to its evolutionary closeness to humans. Four novel cDNAs, encoding cytochro...

HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics.

Arch. Pharm. Res. 38 , 691-704, (2015)

Although various in vitro assays have been developed to evaluate the cytochrome P450 (CYP)-inducing potential of drug candidates, there is a continuing need for the development of a reliable model in ...

Evaluation of the effect of TM208 on the activity of five cytochrome P450 enzymes using on-line solid-phase extraction HPLC-DAD: a cocktail approach.

J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 923-924 , 29-36, (2013)

A rapid, simple, and sensitive on-line solid-phase extraction HPLC-DAD method for simultaneous evaluation of the activity of five CYP450 isoforms (CYP1A2, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) in vivo h...

更多文献

奥美拉唑相关知识

奥美拉唑有哪些副作用？什么人不适合服用奥美拉唑？如何减少依赖？

2022-05-23 18:01:01

患有胃病的人应该知道奥美拉唑，因为奥美拉唑是很好的解胃药。许多人在胃痛时服用奥美拉唑。虽然奥美拉唑有很多优点，但有些人认为奥美拉唑应该有一些副作用。奥美拉唑是否有副作用？当然，答案是肯定的。奥美拉唑是药物。俗话说，药物有三种毒性，所以奥美拉唑也有一些副作用。奥美拉唑被称为质子泵抑制剂，可以抑制胃酸...

奥美拉唑的配伍注意事项有哪些？与其他药物相互作用如何？

2022-05-23 18:11:01

奥美拉唑是临床常用的质子泵抑制剂。胃溃疡治疗：常用剂量20mg，每日1次，4周内治愈；十二指肠溃疡的治疗：常用剂量为20mg，每日一次，可在2周内治愈。所有质子泵抑制剂均为肠溶制剂，不应咀嚼。应在每天早上饭前服用一次。　　一、奥美拉唑的配伍禁忌　　1.1 注射用奥美拉唑不得与其他药物混合或在同一输...

奥美拉唑

奥美拉唑用途

奥美拉唑作用

奥美拉唑名称

奥美拉唑生物活性

奥美拉唑物理化学性质

奥美拉唑MSDS

详细MSDS(安全技术说明书)

奥美拉唑毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

奥美拉唑安全信息

奥美拉唑上下游产品

奥美拉唑上游产品

奥美拉唑下游产品

奥美拉唑制备

奥美拉唑文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

奥美拉唑相关知识

相关化合物